ACAD vs NVST
ACADIA Pharmaceuticals Inc. vs Envista Holdings — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
NVST
Envista Holdings
76
Strong Buy
| Metric | ACAD | NVST |
|---|
| AI Score |
69
|
76
|
| Price |
$29.41
|
$28.51
|
| P/E Ratio |
13.07×
|
48.34×
|
| ROE |
31.9%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
55.5%
|
| Debt / Equity |
0.06×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
59.3
|
| Beta |
0.845
|
0.861
|
| Expected Upside |
—
|
+1.4%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus NVST.
NVST leads by 7 points.
NVST scores 76/100 (Strong Buy) versus ACAD at 69/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.